STINGRAY THERAPEUTICS, INC.
SR-8541A, a small molecule ENPP1 inhibitor for cancer immunotherapy
- Sector
- Biotech
- Headquarters
- DALLAS, TX
- Founded
- 2018
- Latest Form D
- $25K, May 2024
- Total capital
- $7.9M
- Federal grants
- $3.5M
- 3 awards · 2022–2025
- Rank in peer group#173 of 514
- Private capital raised
- $4.5M
- 4 Form D · last May 2024
- 29 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 5
- 17 pending · first 2021
- Rank in peer group#71 of 514
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab$1.5M
- Private capital raisedForm D · SEC · 4th filing$25K
- Private capital raisedForm D · SEC · 3rd filing$437K
- Federal grantHealth and Human S · Phase II · Development of a potent and selective oral ENPP1 inhibitor for oncology$836K
- Private capital raisedForm D · SEC · 2nd filing$3.9M
- Federal grantHealth and Human S · Phase II · Development of a potent and selective oral ENPP1 inhibitor for oncology$1.2M
- Private capital raisedForm D · SEC · 1st filing$52K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#173 · top 34%
- Granted patents#71 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Jonathan P. NorthrupExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Scott Andrew JordanExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Sunil P. SharmaExecutive Officer, Director, PromoterNamed in SEC Form D filings
- Uma P. BhattExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 5 granted of 22- GrantedPhosphonates As Inhibitors Of ENPP1 And CdnpUSPTOUS 12,653,835
- PendingInhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) And Methods Of Use ThereofUSPTOApplication 18902373
- GrantedInhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) And Methods Of Use ThereofUSPTOUS 12,152,015
Show all 22 patent records
- Phosphonates As Inhibitors Of ENPP1 And CdnpJun 16, 2026 · US 12,653,835Granted
- Inhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) And Methods Of Use ThereofMar 20, 2025 · Application 18902373Pending
- Inhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) And Methods Of Use ThereofNov 26, 2024 · US 12,152,015Granted
- Imidazole Compounds As Inhibitors Of ENPP1Feb 1, 2024 · Application 18254686Pending
- Inhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) And Methods Of Use ThereofFeb 28, 2023 · US 11,591,313Granted
- Quinoline And Quinazoline Compounds And Methods Of Use ThereofAug 9, 2022 · US 11,407,729Granted
- Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeuticsOct 12, 2021 · US 11,142,524Granted
- Phosphonates As Inhibitors Of ENPP1 And CdnpApplication 63123298Pending
- Phosphonates As Inhibitors Of ENPP1 And CdnpApplication 63123287Pending
- Imidazole Compounds As Inhibitors Of ENPP1Application 63120597Pending
- Quinoline And Quinazoline Compounds And Methods Of Use ThereofApplication PCTUS2020023091Pending
- Inhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) And Methods Of Use ThereofApplication 62970138Pending
- Substituted 3H-IMIDAZO[4,5-C]PYRIDINE And 1H-PYRROLO[2,3-C]PYRIDINE Series Of Novel Ectonucleotide PYROPHOSPHATASE/PHOSPHODIESTERASE-1 (ENPP1) And Stimulator For Interferon Genes (sting) Modulators As Cancer ImmunotherapeuticsApplication PCTUS2019044756Pending
- Quinoline And Quinazoline Compounds And Methods Of Use ThereofApplication 62820672Pending
- Combinations Of Inhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) With Radiation For Cancer TherapyApplication PCTUS2025059650Pending
- Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeuticsApplication 62713373Pending
- Combinations Of Inhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) With Radiation For Cancer TherapyApplication 63734810Pending
- Phosphonates As Inhibitors Of ENPP1 And CdnpApplication PCTUS2021062329Pending
- Phosphonates As Inhibitors Of ENPP1 And CdnpApplication PCTUS2021062328Pending
- Imidazole Compounds As Inhibitors Of ENPP1Application PCTUS2021061416Pending
- Inhibitors Of Ectonucleotide Pyrophosphatase/phosphodiesterase 1 (ENPP1) And Methods Of Use ThereofApplication PCTUS2021016678Pending
- Phosphonates As Inhibitors Of ENPP1 And CdnpApplication 63123304Pending
Related companies, and why
- NANITE INC.Similar federal contract value in Biotech · null in contracts
- FANNIN PARTNERS LLCSimilar federal contract value in Biotech · null in contracts
- Compass TherapeuticsSimilar federal contract value in Biotech · null in contracts
- IONCOLOGI INCSimilar federal contract value in Biotech · null in contracts
- CORNOVUS PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- APREA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .